Agents for intravitreal administration to treat or prevent disorders of the eye
CA 2366050 C · Owner: Vitreoretinal (Assignment For The Benefit Of Creditors), Llc · Inventors: Castillejos, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing (a) urea, (b) urea derivatives (e.g. hydroxyurea thiourea), (c) a non-steroidal , anti-inflamatory agent (d) antimetabolites, (e) urea, urea derivatives non-, enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g. adenine adenosine, cytosine, cytadine, guanine guanitadine, guanidinium, thymidine, thimitadine uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing nonenzymatic dissolution of the hyaloid membrane or (e) any of the possible combinations thereof, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 2, 2000 and granted May 24, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 2, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 2, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.